• Intravesical p21 mRNA–LNP Therapy for Bladder Cancer

  2026-08-17

  The reference study develops chemically modified p21 mRNA-loaded lipid nanoparticles for localized intravesical tumor suppressor replacement in bladder cancer. Its preclinical data connect restoration of nuclear p21 with cell-cycle inhibition, DNA-damage signaling, apoptosis, and tumor suppression while demonstrating bladder-localized expression with limited transient systemic distribution.

• ICAA, RIP3, and Cardiac Hypertrophy

  2026-08-17

  A 2026 Cellular Signalling study identifies receptor-interacting protein kinase 3 (RIP3) as a direct molecular target of isochlorogenic acid A in angiotensin II- and pressure overload-induced cardiac hypertrophy. The work links RIP3 inhibition to reduced CaMKII activation and shows that this remodeling pathway can operate independently of MLKL, offering a mechanistic framework for cardiovascular disease research.

• Ibrexafungerp Against Fluconazole-Resistant Candida auris

  2026-08-16

  Wiederhold and colleagues combined a 54-isolate in vitro susceptibility analysis with a delayed-treatment murine model to test ibrexafungerp against Candida auris. Ibrexafungerp retained activity across the isolate panel and improved outcomes in infected mice, whereas Fluconazole failed against the resistant isolate used for infection.

• A-1210477: Mapping MCL-1-Dependent Apoptosis

  2026-08-15

  A-1210477 is a selective MCL-1 inhibitor for testing how cancer cells escape mitochondrial apoptosis. This article presents a dependency-mapping framework that connects BIM displacement, BAX/BAK activity, assay design, and translational limitations.

• Romidepsin (FK228, depsipeptide): Lab Guide

  2026-08-14

  A scenario-driven guide to using Romidepsin (FK228, depsipeptide), SKU A8173, in cell viability, proliferation, apoptosis, and epigenetic assays. It covers mechanism, solvent compatibility, 72-hour exposure design, neuroblastoma dose context, HCC combination studies, and practical vendor-selection criteria.

• HyperTrap Heparin HP Column for Assay Design

  2026-08-14

  The HyperTrap Heparin HP Column supports selective sample preparation for signaling and protein studies. This article connects its heparin-based separation principles with the CCR7–Notch1 stemness findings and shows how to make defensible assay decisions without overstating the evidence.

• Rucaparib: Reading DNA Repair and Cell Death

  2026-08-13

  Rucaparib and AG-014699 enable precise DNA damage response research, but interpreting PARP inhibition requires more than a viability endpoint. This guide connects repair-lesion assays with recent insights into RNA Pol II–associated cell death to improve experimental design and mechanistic conclusions.

• Fluconazole and the Next Era of Antifungal Research

  2026-08-13

  Fluconazole remains a powerful benchmark for studying ergosterol disruption, biofilm adaptation, and antifungal drug resistance. This thought-leadership guide connects its target-level mechanism with PP2A-regulated autophagy in Candida albicans and offers a translational framework for designing more predictive susceptibility and infection studies.

• MLN4924 HCl salt: NAE Inhibition Workflows

  2026-08-12

  MLN4924 HCl salt offers a practical way to connect NAE activity with cullin-RING ligase function, protein stability, cell-cycle control, and inflammatory cell death. This guide translates viral RIPK3-degradation findings into controlled biochemical, cellular, and host–pathogen assay workflows with troubleshooting strategies.

• ABT-199: Reliable Apoptosis Assays

  2026-08-12

  Learn how ABT-199 (GDC-0199), Bcl-2 inhibitor, potent and selective (SKU A8194), can improve experimental design, dosing, interpretation, and reproducibility in apoptosis and viability assays. This scenario-based guide connects product formulation data with mitochondrial apoptosis biology and practical laboratory controls.

• SR-202 for PPARγ Metabolic Research

  2026-08-11

  SR-202 provides a selective chemical switch for testing whether PPARγ activity drives adipogenesis, insulin resistance, or macrophage-state changes. This guide translates its mechanism into practical cell-based workflows, DSS-IBD assay extensions, and troubleshooting strategies for obesity research and type 2 diabetes research.

• Oleic Acid: A Translational Lens on Lipid Metabolism

  2026-08-11

  Oleic Acid (C18:1(9Z)) is more than a lipid-loading reagent: it is a controllable probe of membrane composition, GPCR–ERK signaling, inflammatory phenotypes, and metabolic adaptation. Here is a translational framework for using it with mechanistic discipline.

• Mc-Val-Cit-PABC-PNP: ADC Linker Protocol

  2026-08-10

  Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC peptide linker for antibody-drug conjugate synthesis workflows that require enzyme-responsive payload release. It is supplied as a solid, dissolves in DMSO, and should be handled as a research reagent rather than used in aqueous, diagnostic, clinical, or therapeutic applications.

• Cholesterol in LNP Assays: A Mechanistic Guide

  2026-08-09

  Cholesterol is the principal sterol for membrane organization and a powerful experimental variable in lipid nanoparticle research. This guide connects cholesterol chemistry with assay design, LNP interpretation, and the localized p21 mRNA delivery findings reported in bladder cancer.

• 2-NBDG for Cellular Glucose Uptake Assays

  2026-08-08

  2-NBDG is a fluorescent cellular glucose uptake tracer for flow cytometry, microscopy, and microplate-based glucose metabolism assays. In HepG2 insulin-resistance research, 2-NBDG readouts linked reduced glucose uptake with palmitic-acid exposure and GIGYF2/STAU1/PTEN signaling.

16062 records 1/1071 page Next 12345 下5页 Last page